Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2824]

Cancer loses its sense of time to avoid stress responses

Cancer loses its sense of time to avoid stress responses

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia with no measurable residual disease

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia...

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

From lab to clinic: Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer

From lab to clinic: Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform...

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

AI-driven study reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma

AI-driven study reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma

Researchers lead major treatment overhauls for acute myeloid leukaemia

Researchers lead major treatment overhauls for acute myeloid leukaemia

Potential treatment to bypass resistance in deadly childhood cancer

Potential treatment to bypass resistance in deadly childhood cancer

More from ecancer